Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Smoothol is a menthol-flavored electronic cigarette liquid (e-liquid) primarily associated with the **Blu** brand of e-cigarettes, which is owned by **Fontem Ventures** (a subsidiary of **Imperial Brands**). It is a combination product containing **nicotine**, **propylene glycol**, **vegetable glycerin**, and flavoring agents, most notably **menthol**. In scientific literature, particularly in studies investigating the respiratory effects of vaping (e.g., PMID 35611070), Smoothol is frequently utilized as a standardized flavored e-liquid to assess the pulmonary toxicity of e-cigarette aerosols. Research has demonstrated that inhalation of Smoothol aerosol induces oxidative stress, DNA damage, and the release of pro-inflammatory cytokines, such as IL-6 and IL-8, in human lung epithelial cells and fibroblasts. These effects are attributed to both the pharmacological action of nicotine and the specific flavoring chemicals used to achieve its smooth menthol profile. While marketed as a consumer tobacco product, it is often evaluated in clinical and pre-clinical settings for its potential role in smoking cessation and its comparative toxicity to traditional combustible cigarettes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Smoothol.